This is a preview of subscription content, log in via an institution to check access.
References
Menchen L, et al. Cost-Effectiveness of Tofacitinib for the Treatment of Moderate-to-Severe Ulcerative Colitis after Biologic Failure or Intolerance in Spain. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PGI16, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/96686
Taxonera C, et al. Cost-Effectiveness of Tofactinib for the Treatment of Moderate-to-Severe Ulcerative Colitis after Conventional Therapy in Spain. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PGI17, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/96607
Rights and permissions
About this article
Cite this article
Tofacitinib cost effective for ulcerative colitis in Spain. PharmacoEcon Outcomes News 842, 31 (2019). https://doi.org/10.1007/s40274-019-6423-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6423-3